National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90 monoclonal antibody B3
A radioimmunoconjugate of monoclonal antibody (MoAb) B3 conjugated with isotope yttrium 90. MoAb B3 is a murine MoAb that recognizes a Lewis Y carbohydrate antigen present on the surface of many carcinomas. This radioimmunoconjugate emits beta particles that causes cytotoxicity in tumor cells and has both diagnostic and therapeutic uses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:90 Y-B3
MOAB B3, yttrium Y 90
Y 90 monoclonal antibody B3
Abbreviation:Y90-B3



Previous:yttrium Y 90 DOTA monoclonal antibody HuAFP31, yttrium Y 90 DOTA monoclonal antibody HuPAM4, yttrium Y 90 glass microspheres, yttrium Y 90 humanized epratuzumab, yttrium Y 90 ibritumomab tiuxetan
Next:yttrium Y 90 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody Hu3S193, yttrium Y 90 monoclonal antibody MN-14, yttrium Y 90 resin microspheres, yttrium Y 90-DOTA-chimeric monoclonal antibody cG250

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov